Researchers increased chemotherapy dose intensity by shortening the intervals between cycles, or by sequential administration instead of concurrent administration. It seems that if you increase dose intensity, you might be more likely to eradicate all cancer cells. The current meta-analysis included three types of dose-intensification trials. These included comparisons of:.
Chemotherapy for Breast Cancer | American Cancer Society
This article discusses the rationale for dose-dense therapy and reviews the results with dose-dense adjuvant regimens in recent clinical trials in breast cancer. METHODS: The papers for this review covered evidence of a dose-response relation in cancer chemotherapy; the rationale for dose-intense and specifically dose-dense therapy; and clinical experience with dose-dense regimens in adjuvant chemotherapy for breast cancer, with particular attention to outcomes and toxicity. Moderate and high dose cyclophosphamide, doxorubicin, and fluorouracil within the standard range results in greater disease-free and overall survival than the low dose regimen. The sequential addition of paclitaxel after concurrent doxorubicin and cyclophosphamide also significantly improves survival. Disease-free and overall survival with dose-dense sequential or concurrent doxorubicin, cyclophosphamide, and paclitaxel with filgrastim rhG-CSF; NEUPOGEN support are significantly greater than with conventional schedules q21d. Prospective trials of high-dose chemotherapy have shown no improvement over standard regimens, and toxicity was greater.
By Alice Goodman December 25, Advertisement. Reductions in recurrence with dose-intense chemotherapy were similar in estrogen receptor—positive and estrogen receptor—negative disease and did not differ significantly by tumor type and patient characteristics, including age, hormone receptor status, nodal status, tumor size, and tumor grade. Death from noncancer causes was not significantly different between women treated with dose-dense chemotherapy and those given standard chemotherapy.
Many women diagnosed with early-stage breast cancer with a high risk of recurrence the cancer coming back get chemotherapy after surgery to reduce the risk of recurrence. In some cases, the chemotherapy may be given on a dose-dense schedule. Dose-dense chemotherapy means that the chemotherapy medicines are given every 2 weeks instead of the standard schedule of every 3 weeks.